Bone health in HIV infection

Br Med Bull. 2009:92:123-33. doi: 10.1093/bmb/ldp037.

Abstract

Introduction: Osteoporosis is among the chronic problems emerging as the human immunodeficiency virus (HIV)-positive population ages.

Sources of data: We reviewed the English language bibliography using Pubmed 2.0, Web of Science and Embase for relevant abstracts and articles.

Areas of agreement: The prevalence of low bone mineral density (BMD) and fracture is increased in the HIV-positive population.

Areas of controversy: The pathogenesis is multifactorial; there is some evidence that HIV infection is an independent risk factor and that highly active antiretroviral therapy has adverse skeletal effects.

Growing points: Physicians should routinely review the bone health of all HIV patients.

Areas timely for developing research: More studies of the mechanisms of bone loss, the skeletal effects of antiretroviral therapy and the therapeutic outcome of bone-protective therapy in HIV-positive individuals are needed.

Publication types

  • Review

MeSH terms

  • Antiretroviral Therapy, Highly Active / adverse effects*
  • Bone Density Conservation Agents / therapeutic use
  • Bone Density* / drug effects
  • Bone Diseases, Metabolic / drug therapy
  • Bone Diseases, Metabolic / etiology*
  • Diphosphonates / therapeutic use
  • HIV Infections / complications*
  • Humans
  • Life Style
  • Osteoporosis / chemically induced
  • Osteoporosis / drug therapy
  • Risk Factors

Substances

  • Bone Density Conservation Agents
  • Diphosphonates